← Leaderboards
Maryam Raeeszadeh Sarmazdeh
University Of Nevada Reno
$1,868,842
Attributed
$1,868,842
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $511.2K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,868,842 · 5
By mechanism
P20$457,427 · 1
R35$400,178 · 1
R21$398,512 · 1
S10$312,750 · 1
R03$299,975 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Nevada Reno
Same institution · by research overlap
- Iain L Buxton$4,316,181
- Heather R Burkin$2,595,082
- Jonathan E. Baker$22,951,563
- Scott Danielson Barnett$403,342
Others in their field
Other Emerging Leaders on “Proteins”
- John Damon Chodera · Sloan-Kettering Inst Can Research$50,971,767
- Susan Abushakra · Alzheon, Inc.$47,265,244
- Susan M Landau · University Of California Berkeley$47,252,026
- Timothy Fouts · Advanced Bioscience Laboratories, Inc.$40,723,314
- Chris Karlovich · Leidos Biomedical Research, Inc.$38,534,220
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
Research focus
ProteinsEngineeringSurfaceScaffolding ProteinProtein EngineeringTherapeutic TargetDirected Molecular EvolutionAffinityYeastsVariantAlzheimer&AposBindingEnzymesMatrix Metalloproteinase InhibitorTissue EngineeringMatrix MetalloproteinasesGelatinase BMetalloproteasesPlayFoundationsPre-ClinicalBaseEnzyme Inhibitor DrugsDrug Candidate
Grant awards (7)
Engineering Modular Protein Inhibitors for Selective Targeting of Pathological Biomolecules$400,178
R35 · FY2025 · GM · contact PI
Selective targeting of matrix metalloproteinases for developing preterm labor therapeutics$187,308
R21 · FY2024 · HD · contact PI
Bio-Layer Interferometry (BLI) Octet R8$312,750
S10 · FY2023 · OD · contact PI
Directed evolution of tissue inhibitor of metalloproteinase 3 (TIMP-3) to develop novel Alzheimerâs disease (AD) therapeutics$299,975
R03 · FY2022 · AG · contact PI
Selective targeting of matrix metalloproteinases for developing preterm labor therapeutics$211,204
R21 · FY2022 · HD · contact PI
Engineering selective metalloproteinases inhibitors for developing new therapeutics for neurodegenerative diseases$241,109
P20 · FY2021 · GM · contact PI
Engineering selective metalloproteinases inhibitors for developing new therapeutics for neurodegenerative diseases$216,318
P20 · FY2020 · GM · contact PI